All In Biotech

Drug Trial Radar · NCT04742907

Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery (ERAS) Protocol in Subjects Undergoing Bowel Resection

Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 402 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

402

Actual

Start

Jul 29, 2021

Primary completion

Mar 25, 2024

Study completion May 1, 2024

Sponsor

Lead sponsor
Tsumura USAIndustry
Sponsor type
Industry
First posted
Feb 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, randomized, double-blinded, placebo-controlled study will evaluate the effect of TU-100 on resolution of postoperative ileus (POI) in subjects undergoing open or laparoscopic bowel resection (BR).

Conditions

  • Enhanced Recovery After Surgery

Interventions

  • TU-100Drug

    Treatment with investigational product

  • PlaceboDrug

    Treatment with placebo product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Gastrointestinal Recovery (GIR)Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Florence Site

    Florence, Alabama

  • Gilbert Site

    Gilbert, Arizona

  • Little Rock Site

    Little Rock, Arkansas

  • Duarte Site

    Duarte, California

  • Los Angeles Site #1

    Los Angeles, California

  • Los Angeles Site #2

    Los Angeles, California

  • Palo Alto Site

    Palo Alto, California

  • Sacramento Site

    Sacramento, California

  • Danbury Site

    Danbury, Connecticut

  • Clearwater Site

    Clearwater, Florida

  • Orlando Site

    Orlando, Florida

  • Tampa Site

    Tampa, Florida

  • Weston Site

    Weston, Florida

  • Chicago Site #2

    Chicago, Illinois

  • Chicago Site #1

    Chicago, Illinois

  • Urbana Site

    Urbana, Illinois

  • Lexington Site

    Lexington, Kentucky

  • Metairie Site

    Metairie, Louisiana

  • Boston Site #1

    Boston, Massachusetts

  • Detroit Site

    Detroit, Michigan

  • St. Louis Site

    St Louis, Missouri

  • Newark Site

    Newark, New Jersey

  • Mineola Site

    Mineola, New York

  • New York Site

    New York, New York

  • Stony Brook Site

    Stony Brook, New York

  • Cleveland Site #2

    Cleveland, Ohio

  • Cleveland Site #1

    Cleveland, Ohio

  • Philadelphia Site #2

    Philadelphia, Pennsylvania

  • Pittsburgh Site

    Pittsburgh, Pennsylvania

  • Charleston Site

    Charleston, South Carolina

  • Memphis Site

    Memphis, Tennessee

  • Dallas Site

    Dallas, Texas

  • Fort Worth Site

    Fort Worth, Texas

  • Salt Lake City Site

    Salt Lake City, Utah

  • Roanoke Site

    Roanoke, Virginia

  • Milwaukee Site

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.